Aimmune Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aimmune Therapeutics, Inc.
Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.
Seres and rival Ferring are both hoping to have the first-ever FDA-approved microbiome therapeutic but the US firm has secured a strong commercial partner in Nestlé's Aimmune pharma arm to drive SER-109 over the finishing line.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
- Other Names / Subsidiaries
- Allergen Research Corporation (ARC)